24 results about "Anti angiogenesis" patented technology

A system for treating infantile hemangioma includes a first active substance delivery portion and a second active substance delivery portion. The first active substance delivery part delivers a first active substance to the superficial surface of the skin; the second active material delivery unit delivers a second active material to the deep part of the skin. The first active substance contains a beta receptor blocker, and the second active substance contains an antibiotic. Through verification, the beta receptor blocker and the antibiotic are delivered subcutaneously, and the effect of synergistically enhancing anti-angiogenesis and hardening promotion on infantile hemangioma is achieved.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting human ANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The invention relates to application of IGFBP7 in clinical diagnosis of colorectal cancer and application of IGFBP7 as a drug target. The research shows that the expression quantity of IGFBP7 secreted by tumor endothelial cells is continuously reduced in the colorectal tumor formation process related to inflammation. Functional analysis proves that the endothelial-derived IGFBP7 is secreted into a tumor microenvironment and plays a role in resisting angiogenesis. In addition, the CRC cells can actively ingest the vesicles containing the IGFBP7. The IGFBP7 reduces the activity of a TGF-beta1 signal channel by inhibiting the expression of EGR1, thereby inhibiting the proliferation and migration of tumor cells. What is worthy of attention is that VAPA (Vesicle-associated Membrane Protein Associated Protein A) is identified to be a key factor for mediating IGFBP7 vesicles to be transferred to lysosome, and VAPA promotes the degradation of IGFBP7, so that the cancer suppression function of the IGFBP7 is weakened. The endothelial cell-derived IGFBP7 inhibits the progress of CRC (cyclic redundancy check) through an EGR1 / TGF-beta 1 pathway, and VAPA-mediated lysosome degradation limits the cancer inhibition effect of the endothelial cell-derived IGFBP7. The discovery emphasizes that the endothelial cell-derived IGFBP7 is a promising therapeutic target in the field of colorectal cancer.

The invention relates to structures and preparation methods of nine novel guaiane type sesquiterpene dimer compounds in xylostemma oblongifolium, and applications of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The structures of the compounds are as shown in Figure 1. The invention also relates to a preparation method of the dimer compounds, and an application of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The compound provided by the invention has angiogenesis inhibition activity and can be used for development and application of antitumor drugs.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

Provided is a nanoparticle or a pharmaceutical composition including the same for treating or remitting a neovascularization or an angiogenesis in eye segments, and the nanoparticle includes a hyaluronic acid and a therapeutic peptide. Also provided is a method for inhibiting formation or growth of blood vessels by administration of the nanoparticle or the pharmaceutical composition of the present disclosure to a subject in need thereof.

The invention provides an application of a PRC2 inhibitor compound in anti-angiogenesis, and an application of the PRC2 inhibitor compound in treating, alleviating and / or preventing non-tumor diseases related to anti-angiogenesis. The present invention relates to a use of a compound represented by formula (I), a pharmaceutically acceptable salt, a hydrate, a prodrug, a stereoisomer, a solvate or an isotope labeled compound thereof as a PRC2 inhibitor compound in the treatment, alleviation and / or prevention of non-tumor diseases including age-related macular degeneration and the like, in particular, a use of the compound represented by formula (I), the pharmaceutically acceptable salt, the hydrate, the prodrug, the stereoisomer, the solvate or the isotope labeled compound thereof as a PRC2 inhibitor compound.

The present application provides compounds / compositions, synthetic methods, methods of use. The compounds / compositions are directed to thyroid integrin antagonists conjugated to polymers. The compounds / compositions further include additional substituents that are also conjugated to the polymers. The compounds / compositions exhibit increased absorption across the blood brain barrier and increased retention therein and within tumors. The compounds / compositions can also include improved synthetic scalability, improved purity, improved water solubility, and solid products or intermediates. The compounds / compositions can exhibit improved anti-angiogenic effects, and improved efficacy against diseases, particularly cancers that require blood brain barrier permeability, such as malignant gliomas (GBM).

The application relates to the technical field of traditional Chinese medicine research, in particular to a screening method for quality markers of Aidi preparation. The method comprises the following steps: firstly, qualitatively analyzing chemical components, then quantitatively analyzing components with high content and capable of quantitative determination in traditional Chinese medicine; investigating the influence of light and temperature factors on the content of each component; according to the compatibility law of the monarch, minister, assistant and guide of the original medicinal materials in the compound, attributing the compounds; evaluating the anti-tumor and anti-angiogenesis activities of the candidate Q-markers and their respective synergistic activities of adriamycin in resisting tumor and anti-angiogenesis and reducing myocardial toxicity. Finally, a seven-dimensional spider web of “compatibility-content-stability-anti-tumor cell activity-synergistic DOX anti-tumor activity-anti-angiogenesis activity-synergistic DOX anti-angiogenesis activity” and a four-dimensional spider web of “compatibility-content-stability-reducing DOX cardiotoxicity” are established, and the Q-markers for resisting tumor and protecting heart toxicity of AD are comprehensively analyzed.

The present application relates to a kind of double antibody drug conjugate targeted to PD-L1 and VEGF and its preparation method and application.The general formula of the double antibody drug conjugate is Ab-(L-D) x;In general formula Ab, it is the double antibody targeted to PD-L1 and VEGF, includes PD-L1 antigen binding portion and VEGF antigen binding portion;In general formula L-D, it is connection unit-drug compound, L is connection unit, D is drug molecule, x is selected from the integer in 1~8.The double antibody drug conjugate includes PD-L1 antigen binding portion, VEGF antigen binding portion and drug molecule, and the synergistic efficacy between anti-angiogenesis, PD-L1 immune target and antibody conjugate is realized by reasonable structure design.

This application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compounds may include antibodies such as anti-angiogenic antibodies or anti-VEGF antibodies conjugated to small molecule complement inhibitors by a linker, or anti-complement antibodies conjugated to small molecule inhibitors of VEGF, VEGFR, PDGF, PDGFR, FGF, or FGFR by a linker. The linker conjugating the antibody and drug is hydrolyzable over time within the target eye, thereby allowing both the antibody and drug to exert their functions within the target eye. The compounds and compositions can confer superior efficacy compared to either the antibody or the drug alone due to the synergistic effect of the ADS compounds. Methods for treating age-related macular degeneration using ADS compounds and compositions are also provided.

The present application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases, such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compound may comprise an antibody such as an anti-angiogenic antibody or an anti-VEGF antibody linked to a small molecule complement inhibitor through a linking group; or an anti-complement antibody linked to a small molecule inhibitor of VEGF, VEGFR, PDGF, PDGFR, FGF or FGFR via a linking group. A linking group linking the antibody and the drug may hydrolyze in the eye of the subject over time such that both the antibody and the drug function in the eye of the subject. Due to the synergy of the ADS compounds, the compounds and compositions can confer better efficacy than the antibody or drug alone. Methods of treating age-related macular degeneration using the ADS compounds and compositions are also provided.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting humanANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The invention belongs to the technical field of medicines, and discloses a liposome for resisting angiogenesis and down-regulating PD-L1 protein as well as a preparation method and application of the liposome. According to the invention, the active targeting liposome which is modified by NGR and is co-loaded with axitinib and siRNAPD-L1 is prepared by a film dispersion method and a lipid co-extrusion method. The method is simple in preparation process, low in cost, good in stability and high in repeatability. On one hand, Axi / siRNAPD-L1-coated NGR-Lipo inhibits tumor microangiogenesis, reshapes a tumor vascular system, normalizes tumor vessels, inhibits tumor metastasis and improves a tumor immunosuppression microenvironment; on the other hand, PD-L1 protein on the surfaces of tumor cells is silenced, tumor immune escape is relieved, and tumor immunotherapy is enhanced. The Axi / siRNAPD-L1 coated NGR-Lipo realizes an enhanced anti-tumor effect by combining an anti-angiogenesis therapy and an immune checkpoint blocking therapy. The preparation process of the liposome is simple and rapid, is easy for large-scale and industrial production, and also has a better development prospect in the aspect of clinical application transformation.

The invention provides new materials and associated methods that are designed to address certain complex biological phenomena associated with pathologies such as cancer. In this context, embodiments of the invention disclosed herein can provide a multimodal, multitemporal approach to cancer therapy by, for example, targeting selected tumor vessels using materials designed deliver antineoplastic agents as well as anti-angiogenic agents, immunotherapeutic agents, and / or imaging agents, in a temporally controlled fashion.

An embodiment of the present application provides a stimulus-responsive multi-block copolypeptide comprising a peptide derived from pigment epithelium-derived factor (PEDF), a drug carrier, and a pharmaceutical composition thereof. The drug carrier can exhibit improved antiangiogenic activity by forming a multivalent nanostructure of which the size has been controlled through His-Zn2+ chelation.

The present application relates to the technical field of nanomedicine preparation, and particularly relates to a nanocarrier drug delivery system, a preparation method and application thereof. The nanocarrier drug delivery system comprises: extracellular vesicles loaded with methotrexate, lipid nanoparticles loaded with HIF-1 alpha shRNA plasmid, an outer carrier material and azobenzene; and the outer carrier material is modified with cell-penetrating peptide TAT-AT7. The transmembrane hypoxia-responsive hyaluronic acid nanocarrier drug delivery system prepared by the present application has good penetration and safety, is suitable for eye drop administration for treating ocular vascular proliferative diseases, has precise response drug release capacity for the hypoxic site of the lesion, target capacity for vascular endothelial cells and double treatment effects of synergistic anti-inflammatory and anti-angiogenic, and has a wide application prospect.

The present invention relates to nucleic acid molecules encoding angiostatin, transgene expression cassettes comprising the nucleic acid molecules, and gene delivery systems comprising the transgene expression cassettes. The transgene expression cassettes of the present invention are useful in the treatment of various retinal diseases in which neovascularization is a major pathological mechanism, as well as various cancers.

The application belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of TACE combined with sindibimab and bevacizumab in treating hepatocellular carcinoma and a construction method and application of a FAAP prognosis scoring model. The application develops and verifies a FAAP prognosis scoring system, a new type of composite model integrating four indexes of fibrin degradation product / cholinesterase ratio x 1000 (FCR), aspartate aminotransferase (AST), alpha-fetoprotein (AFP) and portal vein tumor thrombus (PVTT), for predicting the survival of uHCC patients receiving TACE-sindibimab-bevacizumab triple therapy. The tool has instant clinical value, can optimize patient selection, guide adaptive treatment upgrade, and provide a standardized efficacy evaluation basis for exploring the clinical trials of TACE-immunotherapy-anti-angiogenesis combined schemes.

Provided are a salt form of a protein tyrosine kinase inhibitor, a preparation method therefor, and use thereof. The protein tyrosine kinase inhibitor has the ability to inhibit an anti-angiogenesis tyrosine kinase. In addition to effectively antagonizing VEGFR1, VEGFR2, and VEGFR3 tyrosine kinase activities, the protein tyrosine kinase inhibitor has high selectivity for inhibiting EGFR tyrosine kinase activity, and can effectively reduce and avoid side effects, especially the side effects on the eyes, making it safer to use. Compared with a free base of the protein tyrosine kinase inhibitor, the aforementioned salt form of the protein tyrosine kinase inhibitor has significantly improved solubility, relatively high solid stability, and relatively low hygroscopicity, and has very good application value in drug development and industrialization.

The invention discloses a traditional Chinese medicine composition for treating skin toxic reaction of an anti-angiogenesis medicine. The traditional Chinese medicine composition comprises the following components in parts by weight: 8-15 parts of angelica sinensis, 10-20 parts of radix polygoni multiflori preparata, 10-20 parts of wine-processed rhizoma polygonati, 8-15 parts of radix paeoniae rubra, 8-15 parts of cortex phellodendri, 10-20 parts of radix rehmanniae recen, 6-15 parts of tribulus terrestris, 6-15 parts of spina gleditsiae, 8-12 parts of cicada slough, 8-12 parts of schizonepeta, 8-12 parts of fructus kochiae and 4-8 parts of scorpio. And 8-15 parts of cortex dictamni. The traditional Chinese medicine composition for treating the skin toxic reaction of the anti-angiogenesis medicine can effectively control side effects generated by the anti-angiogenesis medicine, can resist the skin toxic reaction from the pathogenesis and quickly relieve symptoms, and is convenient to take, safe and reliable. The invention further provides a traditional Chinese medicine preparation for treating the skin toxic reaction of the anti-angiogenesis medicine.

The invention discloses injectable bioactive matrix hydrogel with an anti-angiogenesis and anti-neurogenesis microenvironment and application of the injectable bioactive matrix hydrogel. The injectable bioactive matrix hydrogel is prepared from bevacizumab, a concentrated growth factor and methacrylic acid chondroitin sulfate. The hydrogel prepared by the invention not only shows excellent injectability and biocompatibility, but also can inhibit pathological vascularization and neurogenesis, polarize macrophages to promote regeneration of M2 phenotype so as to relieve inflammation, and directly enhance deposition of cartilage specific ECM components (such as type II collagen and aggregation proteoglycan). By utilizing the coordinated multi-mechanism strategy, the comprehensive structure and function repair of the degenerated intervertebral disc is realized.